Abstract
Matrix metalloproteinases (MMPs) are widely expressed in atherosclerosis lesions. The disequilibrium of MMPs driving to an overexpression or a lack of its level can be influenced by genetic variations. MMP-3 and MMP-9 may be affected by specific polymorphisms like - 1612 5A/6A and the - 1562C/T respectively. We aim in the present study to investigate prospectively the association between the - 1612 5A/6A MMP-3 and - 1562C/T MMP-9 polymorphisms and clinical outcomes in patients with coronary artery disease (CAD). This study is elaborated to reveal whether one of these polymorphisms is a probable predictor of cardiovascular complications in this CAD cohort. A total of 168 patients with CAD were prospectively followed up over a period of 5 years. Genotypes for the MMP-3 (-1612 5A/6A) and MMP-9 (-1562C/T) polymorphisms were performed using PCR-RFLP. Their levels were measured by ELISA in Sandwich test during the follow-up period, 39 cardiovascular outcomes occurred with 21 repeat targets for revascularization, 3 patients with Myocardial infarction, 8 for heart failure, 5 for Stroke and 2 for cardiovascular mortality. The MMP-3 5A/6A polymorphism was related to the disease on the contrary of the MMP-9 -1562C/T. Patients carrying the 5A allele had a higher level of MMP-3 level and those who carried the 6A allele had lower level (p = 0.04). After applied multivariable Cox-hazard models we revealed that the 6A allele is independently associated to the disease complication. Kaplan-Meier survival test revealed that individuals having the 6A allele had a lower survival rate than those with the 5A allele (p = 0.04). Our study suggests the disruption of the MMP-3 level may be due to the existence of the polymorphism - 1612 residing in its promoter region. MMP-3 can be considered as a marker of diagnosis and prediction in cardiovascular events.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call